Endometrial signals improve embryo outcome: functional role of vascular endothelial growth factor isoforms on embryo development and implantation in mice
Advanced Access publication on August
Endometrial signals improve embryo outcome: functional role of vascular endothelial growth factor isoforms on embryo development and implantation in mice
N.K. Binder 1 2
J. Evans 0 4
D.K. Gardner 2
L.A. Salamonsen 0 3
N.J. Hannan 0 1 2
0 MIMR-PHI Institute for Medical Research , 27-31 Wright St, Clayton 3168 , Australia
1 Translational Obstetrics Group, Department of Obstetrics and Gynaecology, University of Melbourne, Mercy Hospital for Women , Heidelberg, VIC 3084 , Australia
2 Department of Zoology, University of Melbourne , Parkville 3010 , Australia
3 Department of Obstetrics and Gynecology, Monash University , Clayton , Australia
4 Department of Physiology, Monash University , Clayton , Australia
study question: Does vascular endothelial growth factor (VEGF) have important roles during early embryo development and implantation? summary answer: VEGF plays key roles during mouse preimplantation embryo development, with beneficial effects on time to cavitation, blastocyst cell number and outgrowth, as well as implantation rate and fetal limb development. what is known already: Embryo implantation requires synchronized dialog between maternal cells and those of the conceptus. Following ovulation, secretions from endometrial glands increase and accumulate in the uterine lumen. These secretions contain important mediators that support the conceptus during the peri-implantation phase. Previously, we demonstrated a significant reduction of VEGFA in the uterine cavity of women with unexplained infertility. Functional studies demonstrated that VEGF significantly enhanced endometrial epithelial cell adhesive properties and embryo outgrowth. study design, size, duration: Human endometrial lavages (n ¼ 6) were obtained from women of proven fertility. Four-week old Swiss mice were superovulated and mated with Swiss males to obtain embryos for treatment with VEGF in vitro. Preimplantation embryo development was assessed prior to embryo transfer (n ¼ 19 - 30/treatment group/output). Recipient F1 female mice (8 - 12 weeks of age) were mated with vasectomized males to induce pseudopregnancy and embryos were transferred. On Day 14.5 of pregnancy, uterine horns were collected for analysis of implantation rates as well as placental and fetal development (n ¼ 14 - 19/treatment). participants/materials, setting, methods: Lavage fluid was assessed by western immunoblot analysis to determine the VEGF isoforms present. Mouse embryos were treated with either recombinant human (rh)VEGF, or VEGF isoforms 121 and 165. Preimplantation embryo development was quantified using time-lapse microscopy. Blastocysts were (i) stained for cell number, (ii) transferred to wells coated with fibronectin to examine trophoblast outgrowth or (iii) transferred to pseudo pregnant recipients to analyze implantation rates, placental and fetal development. main results and the role of chance: Western blot analysis revealed the presence of VEGF121 and 165 isoforms in human uterine fluid. Time-lapse microscopy analysis revealed that VEGF (n ¼ 22) and VEGF121 (n ¼ 23) treatment significantly reduced the preimplantation mouse embryo time to cavitation (P , 0.05). VEGF and VEGF165 increased both blastocyst cell number (VEGF n ¼ 27; VEGF165 n ¼ 24: P , 0.001) and outgrowth (n ¼ 15/treatment: 66 h, P , 0.001; 74, 90, 98 and 114 h, P , 0.01) on fibronectin compared with control. Furthermore, rhVEGF improved implantation rates and enhanced fetal limb development (P , 0.05). limitations, reasons for caution: Due to the nature of this work, embryo development and implantation was only examined in the mouse.
wider implications of the findings: The absence or reduction in levels of VEGF during the preimplantation period likely affects
key events during embryo development, implantation and placentation. The potential for improvement of clinical IVF outcomes by the addition of
VEGF to human embryo culture media needs further investigation.
study funding/competing interest(s): This study was supported by a University of Melbourne Early Career Researcher Grant
#601040, the NHMRC (L.A.S., Program grant #494802; Fellowship #1002028; N.J.H., Fellowship # 628927; J.E.; project grant #1047756) and
L.A.S., Monash IVF Research and Education Foundation. N.K.B. was supported by an Australian Postgraduate Award. Work at PHI-MIMR Institute
was also supported by the Victorian Government’s Operational Infrastructure Support Program. There are no conflicts of interest to declare.
Key words: embryo / endometrium / implantation / assisted reproduction / vascular endothelial growth factor
Infertility affects 48.5 million people globally
(Mascarenhas et al.,
; while many causes of infertility can be treated with assisted
reproduction therapies, such as IVF, 70 – 75% of IVF cycle attempts will fail.
Those that succeed to a viable pregnancy are at an increased risk of
pregnancy complications and demonstrate a correlation with behavioral and
(Ludwig et al., 2006; Ceelen et al., 2008;
Rinaudo and Lamb, 2008; Scherrer et al., 2012; Dar et al., 2013;
Makinen et al., 2013; Pinborg et al., 2013; Talaulikar and Arulkumaran,
. Therefore, improving current IVF procedures, including embryo
culture conditions and optimizing endometrial receptivity, will likely
improve both pregnancy rates and the long-term health and
developmental outcome for children conceived through IVF. Over the past 30
years there have been considerable advances in clinical embryo culture
techniques, including culturing embryos in low oxygen (Gardner,
2007), addition of important metabolites to the medium
2008; Gardner, 2014)
and the development of sequential culture
media and stage of embryo/blastocyst transfer
(Gardner and Lane,
1997; Papanikolaou et al., 2006a,b)
, which resulted directly in an increase
in implantation rates and a decrease in pregnancy loss
et al., 2006a)
. However, even with these advancements in embryo
culture, there is still a 70 – 75% IVF failure rate. An improved
understanding of the ‘physiological’ microenvironment of preimplantation embryo
development in vivo will likely lead to a more optimal pregnancy outcome.
The proteins present in the uterine secretions may be important for
endometrial-embryonic communication and therefore improved
preimplantation development. Throughout most of the human menstrual cycle
the endometrium is hostile or non-receptive to embryo implantation.
For a short window of time, 5 – 9 days following ovulation, the
endometrium becomes receptive to allow blastocyst implantation
and Bergh, 1991)
. At this time the glandular and luminal epithelium
become highly secretory, producing and secreting a wide array of
factors into the uterine cavity
(Gray et al., 2001; Burton et al., 2002;
Hempstock et al., 2004; Hannan et al., 2010)
. Thus, the blastocyst is
bathed in maternal uterine secretions from the time it first enters the
uterine cavity and throughout the peri-implantation period.
Disrupted secretion of individual soluble factors including cytokines,
growth factors and proteases from the endometrium into the uterine
lumen has been correlated with infertility
(Dimitriadis et al., 2006;
Mikolajczyk et al., 2006; Boomsma et al., 2009)
. Studies identifying the
products of glandular secretions, bioactivity and function are therefore
a necessary prerequisite to further understand endometrial receptivity
and maternal-embryonic communication and to increase the efficacy
of in vitro culture conditions. In addition, there are currently no definitive
markers of endometrial receptivity which can reliably identify receptive
endometrium during IVF procedures.
Previously, we assessed the cytokine and growth factor profile of
human uterine fluid using multiplex assays
(Hannan et al., 2011)
both fertile and infertile women during the mid-secretory phase.
Women with unexplained infertility had overall reduced levels of vascular
endothelial growth factor A (VEGFA). Importantly, we further
demonstrated that VEGFA has substantial effects on both endometrial epithelial
receptivity (adhesive capacity) and on blastocyst outgrowth in vitro
(Hannan et al., 2011)
VEGF is most well known for its roles in angiogenesis, driving both
endothelial cell proliferation and migration. Both VEGF receptor 1
(VEGFR1) and VEGF receptor 2 (VEGFR2) are expressed by mouse
(Baston-Buest et al., 2011)
. There are three secreted isoforms of
VEGFA, namely VEGF121, VEGF145 and VEGF165, the two most
abundant being VEGF121 and VEGF165, both signal through VEGFR-2. We
therefore examined the role of both VEGF121 and VEGF165 on the
Our previous study identified, for the first time, a non-vascular role of
endometrial-derived VEGFA with functional actions on the maternal
surface and on the peri-implantation blastocyst
(Hannan et al., 2011)
The current study aimed to further characterize the role of VEGF on
the peri-implantation embryo. We identified the predominant VEGF
isoforms secreted into the human uterine cavity by western blot, revealing
that both VEGF121 and 165 isoforms are present. These isoforms and
total VEGF were added to mouse embryo cultures and embryos were
monitored using high temporal time-lapse microscopy, examining
blastocoel formation and hatching. Embryos were then analyzed for (i) cell
number, (ii) blastocyst outgrowth or (iii) transferred to pseudo pregnant
recipient females to analyze implantation rates, and placental and embryo
development. Supplementing culture media with VEGF, VEGF121 and
VEGF165 had beneficial effects on post-compaction mouse embryo
development, outgrowth, implantation and fetal development.
Materials and Methods
Ethical approval was obtained from Monash Surgical Private Hospital; Human
Research Ethics Committee (Project No. 04056) and Southern Health
Human Research Ethics Committee (Project No. 03066B) for all human
sample collections. Written informed consent was obtained from all subjects
prior to sample collection. Ethical approval was obtained from the University
of Melbourne Animal Ethics Committee (Project ID: 0811074.2) prior to
experimentation. All animal experimentation was conducted in accordance
with accepted standards of humane animal care, as outlined in the Ethical
Guidelines of the National Health and Medical Research Council.
Sample collection and patient details
Human endometrial lavage fluid (n ¼ 6/group) was obtained from women
with proven fertility (undergoing tubal ligation) and women of unknown
fertility status and with unexplained infertility during the late proliferative – early
secretory phase (Days 14 – 19) of the menstrual cycle who were undergoing
hysteroscopy, dilatation and curettage. Cycle stage was confirmed by
histological dating, according to the criteria of
Noyes et al., (1975
). The infertile
women had been screened for non-endometrial causes of their infertility,
tubal patency and their partner did not have male factor infertility. Patients
with uterine abnormalities, such as endometrial polyps, fibroids,
endometriosis and endometritis, or who had received steroid hormone therapy in the
last 6 months were excluded from the study. As previously described
(Hannan et al., 2009, 2010, 2011, 2012)
, prior to hysteroscopy 3 ml of
sterile saline was gently infused into the uterine cavity through a fine flexible
catheter for a few seconds; the saline solution was then aspirated and
centrifuged to remove contaminating cellular debris (including leukocytes, red
blood cells and mucous) and stored at 2808C as 0.5 ml aliquots.
Heparin capture of uterine lavage fluid
Heparin agarose suspension (100 ml) (heparin agarose, H6508,
Sigma-Aldrich) was loaded on to Pierce spin columns (69705, Pierce).
Storage buffer was removed by centrifugation at 1000g for 5 min, and
agarose washed three times with 0.01 M Tris – HCl. Uterine lavage fluid
(100 ml) (equal amounts pooled from n ¼ 6 women) was mixed with
100 ml of binding buffer (0.01M Tris – HCl), added to washed heparin
agarose and incubated at room temperature for 90 min with end over end
mixing. Unbound proteins were removed by centrifugation at 1000g for
5 min and weakly bound proteins were removed with 0.01 M Tris – HCl/
150 mm NaCl. Heparin-bound proteins were removed by three sequential
elutions with 200 ml 0.01 M Tris – HCl/2M NaCl. Eluted proteins were
dialyzed and concentrated to 50 ml with phosphate-buffered saline (PBS) using
3 kDa cut-off spin filters.
Western immunoblot analysis
Fifty nanograms of recombinant VEGF121, VEGF165 or 50 ml of
heparinbound proteins was mixed with 5× non-reducing loading buffer, heated to
958C for 5 min and loaded on to a 15% sodium dodecyl sulphate
polyacrylamide gel electrophoresis gel. Protein was blotted onto 0.45 mm PVDF
transfer membrane (GE Healthcare) using a TransBlot turbo transfer system
(BioRad). Immunoblots were washed in 0.1% Tris-buffered saline (TBS) –
Tween 20 before incubation in 5% skim milk/0.1% TBS – Tween 20 to
block non-specific binding. Immunoblots were then washed in 0.1% TBS –
Tween 20 before incubation with goat anti-VEGF antibody (R&D Systems)
at a 1:500 dilution overnight at 48C. Immunoblots were washed thoroughly
in 0.1% TBS – Tween 20 before incubation with rabbit anti-goat horse-radish
peroxidase antibody (Dako) at 1:200 dilution at room temperature for 1 h.
After washing in 0.1% TBS – Tween 20, enhanced chemiluminescence
(ECL, BioRad) was applied and immunoreactive bands visualized using a
Chemidoc XRS+ system (BioRad). Recombinant human (rh) VEGF was
used as a positive control to confirm antibody specificity.
Animals and hormonal stimulation
Four-week old Swiss female mice (n ¼ 50) were superovulated with
intraperitoneal injections of 5 IU pregnant mare’s serum gonadotrophin (Folligon;
Intevet, UK) followed 48 h later by 5 IU hCG (Chorulon; Intervet). Females
were mated with Swiss males overnight. The presence of a vaginal plug the
following morning was used as an indicator of successful mating.
Embryo collection and culture
Pronucleate oocytes (n ¼ 400) were collected 21–22 h post-hCG in
G-MOPS embryo handling medium
5 mg/ml human serum albumin (HSA) (Vitrolife, Sweden), followed by
cumulus removal in G-MOPS (Vitrolife) containing 300 IU/ml
hyaluronidase (bovine testes, type IV; Sigma-Aldrich). Pronucleate oocytes were
removed from the hyaluronidase immediately once the cumulus cells had
detached, washed twice in G-MOPS and then once in G1 medium
before culture. Pronucleate oocytes were then
combined and randomly assigned to different treatment groups, either cultured
in 20 ml (Group: 10 embryos/drop) or 2 ml (individual; single embryo/
drop) drops of G1 medium supplemented with 5 mg/ml HSA under
paraffin oil (Ovoil; Vitrolife) at 378C in 6% CO2, 5% O2 and 89% N2.
After 48 h, embryos were randomly transferred into their respective
treatment media either in groups (20 ml) or as individuals (2 ml): (i) control; G2
with 5 mg/ml HSA; (ii) total VEGF
containing rhVEGF (R&D systems, Minneapolis, MN, USA) at a dose of
50 ng/ml in G2 control media, as previously established
(Hannan et al.,
; (iii) VEGF121 containing 50 ng/ml rhVEGF isoform 121 (IsokineTM
ORF Genetics, Keldnaholt, Iceland) in G2 media and (iv) VEGF165
containing 50 ng/ml rhVEGF isoform 165 (IsokineTM ORF Genetics) in G2 media.
Embryos were cultured under paraffin oil (Ovoil) at 378C under the same
gas phase conditions to the blastocyst stage.
Embryos being analyzed for development and cell cycle kinetics were
cultured individually in 2 ml drops of G1 medium supplemented with 5 mg/ml
HSA under paraffin oil (Ovoil, Vitrolife) in the same gas phase conditions at
378C in a humidified multi-gas imaging incubator (Sanyo MCOK-5M[RC])
for 48 h and then transferred to treatment groups (as detailed above).
Timelapse images of individual embryos were generated every 15 min across
culture using the imaging incubator. From these images, the timing of the
start of cavitation and hatching were calculated as hours post-hCG.
Blastocyst cell number was determined following final morphological
assessment at 114 h post-hCG (Day 5) as described previously
(Hannan et al.,
2011; Binder et al., 2012)
. Blastocysts (n ¼ 24 – 30 per treatment group)
were stained in a solution of 0.1 mg/ml Bisbenzimide (Hoescht 33342;
Sigma Chemical Co.) in 10% ethanol, for 1 h at 378C, and rinsed in
G-MOPS with 5 mg/ml HSA. Blastocysts were mounted in glycerol under
cover slips on glass slides before being observed under fluorescent light
(Nikon TS100-F), and cell numbers counted manually.
Blastocyst outgrowth was assessed as described previously
(Hannan et al.,
. In brief, flat bottomed 96-well tissue culture dishes (BD Biosciences,
USA) were coated with fibronectin (Fn) (10 mg/ml) (BD Biosciences), rinsed
twice with sterile PBS and incubated with 4 mg/ml bovine serum albumin
(Sigma Diagnostics, St. Louis, USA). Wells were rinsed and subsequently
filled with 150 ml of appropriate experimental medium and equilibrated at
378C under paraffin oil (Ovoil) for 3 h prior to the addition of blastocysts.
Hatched blastocysts (on Day 5 of development) that had been pre-cultured
in appropriate medium were placed into the coated wells (1 embryo per
well) and incubated for 114 h. Outgrowth was examined and images were
taken at a matching magnification (×10) at sequential times (66, 74, 90, 98
and 114 h following transfer to outgrowth plate) during the culture period
with an inverted microscope (Eclipse TS100-F; Nikon, Coherent Scientific
Pty. Ltd., SA, Australia) equipped with heated stage at 378C. The extent of
outgrowth for each treatment was obtained by measuring the area of outgrowth in
each of the images taken across the experiment using NIS Elements BR 3.00,
SP7 Laboratory Imaging software (Nikon). All images were analysed at matching
magnification. The average area of outgrowth was calculated for each treatment
group: (i) control; (ii) VEGF; (iii) VEGF121 and (iv) VEGF165 with n ¼ 15 embryos
in total per treatment (n ¼ 5/experiment, and the experiment was repeated
three times). Data are expressed as mean outgrowth + SEM.
Embryo transfer, implantation and fetal development
F1 female mice between 8 and 12 weeks of age were mated with
vasectomized males to induce pseudopregnancy. Mating was confirmed by the
presence of a vaginal plug. Embryos were transferred on Day 4.5 of development
(asynchronous to female reproductive tract which was staged as Day 3.5 of
pregnancy). Recipient female mice were anesthetized with an intraperitoneal
injection of ketamine (75 mg/kg Ketalar, Pfizer, Australia) and
medetomidate (1 mg/kg Domitor, Pfizer, Australia). Five embryos were transferred
through a small dorsal incision with a glass pipette into the lumen of each
uterine horn. Recipient female mice received embryos cultured in media
treatment groups as described above: (i) control; (ii) total VEGF, 50 ng/ml
of rhVEGF; (iii) VEGF121, 50 ng/ml of rhVEGF isoform 121 and (iv)
VEGF165, 50 ng/ml of rhVEGF isoform 165. Alternate groups were
transferred to both the right and left horn per recipient to avoid any preferential
implantation bias of the left or right horn. Following embryo transfer, the
skin wound was sealed with sterile surgical clips, and the recipient female
underwent post-operative recovery with an intraperitoneal injection of
atipamezole (1 mg/kg Antisedan, Pfizer, Australia) to reverse the effects of
medetomidate. Pregnant females were sacrificed 10 days later (Day 14.5 of fetal
development). The number of fetuses and implantation/absorption sites
were recorded to determine the rates of implantation and fetal
development. Fetal and placental weight was recorded and crown-rump length
measured. Fetal ear, eye and limb development was assessed as reported
(Wahlsten and Wainwright, 1977; Lane and Gardner, 1994;
Binder, Hannan and Gardner, 2012)
After testing for normal distribution, statistical analysis was performed on raw
Time-lapse (embryo developmental kinetics): the time, in hours (h) from
hCG, to cavitation and to hatching was not normally distributed and
statistically analysed with a non-parametric Mann – Whitney test. Blastocyst cell counts
were normally distributed and statistically analysed by analysis of variance
followed by Tukey’s multiple comparison test. Embryo outgrowth data were not
normally distributed and were tested non-parametrically using the Kruskal –
Wallis test. Embryo implantation following transfer—the proportion of
embryos implanted per transfer was assessed; data were not normally
distributed and were analysed using a Kruskal – Wallis test. Fetal and placental
development: weight (g), crown-rump length (mm) and fetal morphological
grade (not normally distributed) were analysed with a Kruskal – Wallis test
(non-parametric). P values , 0.05 were taken as significant. All statistical
analysis was carried out using PRISM version 6.00 for Mac (GraphPad,
SanDiego , CA, USA).
VEGF isoforms are present in receptive phase human uterine fluid
Western immunoblot analysis following heparin capture of human
uterine lavage fluid revealed two bands corresponding with the
VEGF121 ( 28 kDa) and VEGF165 ( 38 kDa) molecular weight
(Fig. 1). VEGF121 appears to predominate in heparin-captured uterine
VEGF enhanced embryo development
Mouse embryos treated with either VEGF (n ¼ 22) or the VEGF121
isoform (n ¼ 23) cavitated significantly earlier compared with control
embryos (n ¼ 19) (Fig. 2A). VEGF165 (n ¼ 24) treatment had no
significant effect on time to cavitation (Fig. 2A). Blastocyst hatching rates were
variable but no significant difference in hatching rates were observed with
treatment (data not shown).
VEGF enhanced blastocyst cell number
Mouse blastocyst cell number was significantly increased when either
VEGF (n ¼ 27) or VEGF165 (n ¼ 24) was added to the culture media
(Fig. 2B) compared with control (n ¼ 28) (control 88 + 26 cells versus
VEGF 101 + 12 cells; P , 0.001; control 88 + 26 cells versus
VEGF165 114 + 27 cells; P , 0.001). Addition of VEGF121 (n ¼ 29)
to the culture had no effect on blastocyst cell number (Fig. 2B).
VEGF enhanced blastocyst outgrowth in vitro
Mouse embryos were used to assess the functional effects of VEGF,
VEGF121 and VEGF165 on blastocyst outgrowth in vitro. A significant
increase in the area of blastocyst outgrowth was observed with rhVEGF
treatment (Fig. 2C; n ¼ 15). VEGF121 treatment (n ¼ 15) increased
outgrowth area (P , 0.05; 66 h post-hatching) compared with control
cultured embryos (Fig. 2D; n ¼ 15). VEGF165 (n ¼ 15) caused a highly
significant increase in outgrowth (at all time points examined; 66 h
(P , 0.001), 74, 90, 98 and 114 h (P , 0.01) compared with control
(Fig. 2D), while VEGF121 was without effect after 66 h.
Figure 1 Vascular endothelial growth factor in human uterine lavage
fluid. Heparin capture and western blot analysis revealed the presence
of two VEGF isoforms in human uterine lavage fluid. Both VEGF isoforms
121 ( 28 kDa) and 165 ( 38 kDa) are abundant. Lane 1: molecular
mass (Mr) markers are included to indicate Mr; Lane 2: lavage fluid
from ‘Fertile’ women (n ¼ 6 pooled); Lane 3: lavage fluid from
‘women of unknown fertility’ (n ¼ 6 pooled); Lane 4: lavage fluid from
‘Infertile’ women (n ¼ 6 pooled). The dotted lines demarcate the
borders between two juxtaposed images due to the removal of two
lanes with over-developed VEGF signal.
Data are expressed as mean + SEM.
*P , 0.05 versus control. Embryo implantation following transfer (proportion of embryos implanted per transfer) was assessed statistically using a Kruskal –Wallis test (n ¼ 28–41/
VEGF improves embryo implantation rates and limb development
Mouse embryos cultured with rhVEGF had significantly higher
implantation rates following blastocyst transfer compared with control
(P , 0.05) (Table I). VEGF121 showed an overall improved implantation
rate compared with control, but this was not significant. Whilst not
significant, there was a trend for embryos cultured in rhVEGF to have higher
rates of ongoing pregnancy per transfer and embryos cultured in
rhVEGF165 also showed a trend to higher rates of ongoing pregnancy
per implantation (Table I).
Implanted embryos were further characterized at embryonic Day 14.5
to examine development. There was a significant advance in fetal limb
development when VEGF165 was present during embryo culture (Fig. 3A).
In particular, preimplantation embryo culture in VEGF165 resulted in
embryos with clearly defined, webbed digits at this time (Fig. 3B)
compared with those derived from control embryos (Fig. 3C).
Neither fetal nor placental weights were significantly altered when
rhVEGF or the two isoforms were added to the embryo culture
medium: neither were there significant differences in crown-rump
length, eye or ear morphology (Table II).
Previously, we identified that VEGFA was significantly reduced in uterine
lavage fluid in women with unexplained infertility
(Hannan et al., 2011)
and that functionally, VEGF acted on both human uterine epithelium
and on mouse embryo attachment and outgrowth in vitro
et al., 2011)
. The current study identifies that the predominant VEGF
isoforms secreted into the human uterine cavity are VEGF121 and 165.
Addition of VEGF, VEGF121 and VEGF165 to embryo culture
postcompaction enhanced preimplantation mouse embryo development
(reduced time to cavitation and increased blastocyst cell number).
Consistent with our previous findings addition of total rhVEGF
enhanced blastocyst outgrowth in vitro. In the present study, the
addition of the VEGF121 and VEGF165 isoforms caused a significant
increase in blastocyst outgrowth compared with control. Furthermore,
this study demonstrates for the first time that VEGF and its secreted
isoforms VEGF121 and VEGF165 enhanced implantation rates and fetal
limb development in mice.
VEGF is most well known for its roles in angiogenesis. The VEGF family
(consisting of five members: VEGFA, VEGFB, VEGFC, VEGFD and
placental growth factor) and their receptors are key mediators of vascular
growth and remodeling in a variety of tissues, including the human
Figure 3 Morphological assessment of mouse fetal limb development
on Day 14.5 of pseudopregnancy. Embryos pre-cultured with VEGF165
had improved fetal morphological limb development compared with
controls (A). Data expressed as mean + SEM. *P , 0.05 versus control
(n ¼ 14– 19/treatment). Data were tested non-parametrically using
Kruskal – Wallis. Representative images of forelimb development in
fetuses derived from embryos cultured in standard IVF media (B)
compared with those cultured with VEGF165 (C). Defined digits are observed
in the fetus at Day 14.5 of pregnancy in the VEGF165 group compared
with the standard IVF media group (×4 magnification).
(Hornung et al., 1998; Girling and Rogers 2009)
binds to and signals via two tyrosine kinase receptors, VEGFR1 and
VEGFR2, both of which are immunolocalized apically in endometrial
glandular epithelium (Moller et al., 2001). VEGFA enhances the
mitogenic activity of endothelial cells via the adhesion molecule integrin avb3
(Soldi et al., 1999)
, an important adhesion molecule during embryo
implantation and a potential marker of endometrial receptivity
2002; Illera et al., 2003)
. VEGF is expressed by granulated metrial
glands in the murine uteri (Wang et al., 2000). Both VEGFR1 and 2 are
expressed by mouse blastocysts
(Baston-Buest et al., 2011)
. There are
three secreted isoforms of VEGFA, namely VEGF121, VEGF145 and
VEGF165, the two most abundant being VEGF121 and VEGF165
(Poltorak et al., 1997; Nakatsu et al., 2003)
. While VEGF121 and
VEGF165 have similar functions, it has been suggested that VEGF165
may be more potent than 121
(Ke et al., 2002)
and while VEGF165
and VEGF121 bind to their receptors with equal affinity, their ability to
activate VEGFR-2 is not equivalent
(Keyt et al., 1996; Soker et al.,
1997; Ogawa et al., 1998)
. Therefore, we examined the role of both
VEGF121 and VEGF165 on the preimplantation embryo.
VEGFA is expressed in both human endometrial endothelial and
(Moller et al., 2001)
and is readily detected in uterine fluid,
supporting its secretion by endometrial epithelium
(Hannan et al.,
into the microenvironment where the blastocyst undergoes its
final development for implantation. Moreover, its secretion is increased
in the presence of the blastocyst-derived factor, hCG
(Paiva et al., 2011)
highlighting a mechanism by which the presence of a human blastocyst
could enhance receptivity
(Licht et al., 2001)
. Furthermore, VEGFA is
significantly reduced in the mid-secretory phase in uterine fluid from
infertile women compared with women of proven fertility
(Hannan et al.,
. Given that VEGF can exist in a number of isoforms that can
have different actions and potency, identification of the specific isoforms
secreted into the uterine cavity was important. Using western blot
analysis we showed that heparin-binding forms of VEGF121 and 165 were
readily detectable in human uterine fluid. These likely represent the
active forms present in vivo as it is known that they bind to heparin and
this binding enhances their potency (Ashikari-Hada et al., 2005).
While embryo culture has improved over the past 30 years, in vitro
cultured embryos have been observed to typically develop more slowly and
have reduced blastocyst cell numbers than embryos developed in utero
(Bowman and McLaren, 1970, Paria and Dey, 1990)
. Analysis of media
used to support human embryos in clinical IVF shows that until the
mid-1990s the media were based on simple salt solutions supplemented
with glucose, pyruvate, lactate and HSA (Quinn et al., 1985). Such culture
media have been shown to impart significant stress to the developing
mammalian embryo from the zygote to blastocysts stage
Lane, 2005; Lane and Gardner, 2005)
. Human embryo culture media
have become more complex and effective over the past 15 years, and
now include amino acids and vitamins (Gardner, 2008). However
media used in human IVF typically lack key regulators of development
present in many other culture media, particularly growth factors
and cytokines. Recently, the addition of granulocyte – macrophage
colony-stimulating factor (GM-CSF) has been evaluated in human IVF,
where a significant increase in survival of transferred embryos was
observed but only when the embryos were cultured at reduced levels
of HSA (2 mg/ml)
(Ziebe et al., 2013)
. Furthermore, in our previous
work analyzing the abundance of cytokines and growth factors in
human uterine fluid, we observed higher levels of VEGF compared
with GM-CSF in the uterine cavity
(Hannan et al., 2011)
Using sophisticated time-lapse analysis we demonstrated here that
rhVEGF and the specific VEGF121 isoform significantly improved
on-time blastocoel cavity formation. Furthermore, embryos cultured
in the presence of either VEGF or VEGF165 had significantly increased
cell numbers compared with embryos cultured in standard IVF media.
The potential effect of VEGF and its isoforms on embryos during
culture post-compaction was also assessed by blastocyst outgrowth
(a functional in vitro analysis of embryo implantation potential). As
(Hannan et al., 2011)
, addition of VEGF to standard IVF
culture media significantly increased outgrowth area. The present study
extended these findings demonstrating that both VEGF121 and
VEGF165 significantly increase outgrowth area by .5-fold.
Any benefit of adding VEGF to embryo culture in terms of pregnancy
rates and embryo development was assessed in vivo following embryo
transfer to pseudo pregnant recipients. Addition of rhVEGF to embryo
culture media caused a significantly increased implantation rate
compared with control standard IVF media. Whilst not significant but
perhaps more importantly when considering the quality and health of
the pregnancy, VEGF165-treated embryos showed a trend towards
increased number of viable pregnancies following transfer.
Interestingly, of a number of other parameters examined (placental
and fetal weights, embryo crown-to-rump length, eye or ear
development), the only change observed with VEGF was that of limb
development. In fetuses developing in vivo from embryos cultured in standard
IVF medium there was a lack of defined digitation at Day 14.5 of
pregnancy compared with those embryos that were cultured in media
supplemented with VEGF165.
Taken together, the data in mice clearly demonstrate that the addition
of both VEGF isoforms VEGF121 and VEGF165 to embryo culture
medium has benefits compared with standard IVF media. VEGF121
and VEGF165 have unique actions at different stages of preimplantation
embryo development and both are abundant in the human uterine
microenvironment during the peri-implantation phase. Therefore,
addition of VEGF121 and VEGF165 should be considered for use in
human embryo culture medium. A randomized controlled prospective
clinical trial should be considered to test the efficacy of VEGF121 and
VEGF165 in humans.
We previously identified high levels of VEGFA in human uterine fluid in
women during the window of implantation and that this was significantly
reduced in women with unexplained infertility. Here we demonstrate
that VEGF121 and VEGF165 are the major isoforms in the human
uterine cavity and that addition of rhVEGF to mouse embryo culture
significantly improves preimplantation embryo development and embryo
outgrowth in vitro. Furthermore, improvements in mouse implantation
rates and aspects of fetal development in vivo were identified. These
findings further support the concept that there is a precise paracrine and
autocrine dialog between the blastocyst and endometrial epithelium
during embryo implantation, and clearly highlight the importance of
the changing microenvironment as embryos develop. Furthermore,
the potential for improvement of clinical IVF outcomes by the addition
of VEGF to human embryo culture media needs further investigation.
The authors thank research nurse Judi Hocking and the clinical staff at
Monash IVF and Monash Medical Centre (Southern Health sites) for
collection of endometrial lavage samples and in particular, the women who
generously consented to the procedure.
All authors contributed to the conception and design of experiments, or
the acquisition of data, or analysis and interpretation of data, manuscript
preparation and revision, as well as final approval for publication.
This study was supported by a University of Melbourne Early Career
Researcher Grant #601040, the NHMRC (LAS, Program grant #494802;
Fellowship #1002028; NJH, Fellowship # 628927; JE; project grant
#1047756) and LAS, Monash IVF Research and Education Foundation.
N.K.B. was supported by an Australian Postgraduate Award. Work at
PHI-MIMR Institute was also supported by the Victorian Government’s
Operational Infrastructure Support Program.
Conflict of interest
D.K.G. receives grant support from Vitrolife AB. This funding does not
cover any work presented here.
Ashikari-Hada S , Habuchi H , Kariya Y , Kimata K. Heparin regulates vascular endothelial growth factor165-dependent mitogenic activity, tube formation, and its receptor phosphorylation of human endothelial cells. Comparison of the effects of heparin and modified heparins . J Biol Chem 2005 ; 280 : 31508 - 31515 .
Baston-Buest DM , Kruessel JS , Ingmann SC , Hirchenhain J , Janni W , Hess AP . In vitro culture does not alter the expression of vascular endothelial growth factor and its receptors in single murine preimplantation embryos . Gynecol Obstet Invest 2011 ; 71 : 24 - 31 .
Binder NK , Hannan NJ , Gardner DK . Paternal diet-induced obesity retards early mouse embryo development, mitochondrial activity and pregnancy health . PLoS One 2012 ; 7 : e52304 .
Boomsma CM , Kavelaars A , Eijkemans MJ , Amarouchi K , Teklenburg G , Gutknecht D , Fauser BJ , Heijnen CJ , Macklon NS . Cytokine profiling in endometrial secretions: a non-invasive window on endometrial receptivity . Reprod Biomed Online 2009 ; 18 : 85 - 94 .
Bowman P , McLaren A . Cleavage rate of mouse embryos in vivo and in vitro . J Embryol Exp Morphol 1970 ; 24 : 203 - 207 .
Burton GJ , Watson AL , Hempstock J , Skepper JN , Jauniaux E. Uterine glands provide histiotrophic nutrition for the human fetus during the first trimester of pregnancy . J Clin Endocrinol Metab 2002 ; 87 : 2954 - 2959 .
Ceelen M , van Weissenbruch MM , Vermeiden JP , van Leeuwen FE , Delemarre-van de Waal HA . Cardiometabolic differences in children born after in vitro fertilization: follow-up study . J Clin Endocrinol Metab 2008 ; 93 : 1682 - 1688 .
Dar S , Librach CL , Gunby J , Bissonnette F , Cowan L , Fertility IVF , DGoC Andrology Society . Increased risk of preterm birth in singleton pregnancies after blastocyst versus Day 3 embryo transfer: Canadian ART Register (CARTR) analysis . Hum Reprod 2013 ; 28 : 924 - 928 .
Dimitriadis E , Stoikos C , Stafford-Bell M , Clark I , Paiva P , Kovacs G , Salamonsen LA . Interleukin- 11 , IL -11 receptoralpha and leukemia inhibitory factor are dysregulated in endometrium of infertile women with endometriosis during the implantation window . J Reprod Immunol 2006 ; 69 : 53 - 64 .
Gardner DK . Dissection of culture media for embryos: the most important and less important components and characteristics . Reprod Fertil Dev 2008 ;20: 9 - 18 .
Gardner DK , Lane M. Culture and selection of viable blastocysts: a feasible proposition for human IVF? Hum Reprod Update 1997 ; 3 : 367 - 382 .
Gardner DK , Lane M. Ex vivo early embryo development and effects on gene expression and imprinting . Reprod Fertil Dev 2005 ; 17 : 361 .
Gardner DK , Lane M. Embryo culture systems . In: Gardner DK (ed.). In Vitro Fertilization-A Practical Approach . New York: Informa Healthcare, 2007 , 221 - 282 .
Gardner DK , Lane M. Culture of viable mammalian embryos . In: Cibelli J RL, Campbell K , West MD (eds) . Principles of Cloning . San Diego: Academic Press, 2014 , 63 - 84 .
Girling JE , Rogers PA . Regulation of endometrial vascular remodelling: role of the vascular endothelial growth factor family and the angiopoietin-TIE signalling system . Reproduction 2009 ; 138 : 883 - 893 .
Gray CA , Bartol FF , Tarleton BJ , Wiley AA , Johnson GA , Bazer FW , Spencer TE . Developmental biology of uterine glands . Biol Reprod 2001 ; 65 : 1311 - 1323 .
Hannan NJ , Stoikos CJ , Stephens AN , Salamonsen LA . Depletion of high-abundance serum proteins from human uterine lavages enhances detection of lower-abundance proteins . J Proteome Res 2009 ; 8 : 1099 - 1103 .
Hannan NJ , Stephens AN , Rainczuk A , Hincks C , Rombauts LJ , Salamonsen LA . 2D-DiGE analysis of the human endometrial secretome reveals differences between receptive and nonreceptive states in fertile and infertile women . J Proteome Res 2010 ; 9 : 6256 - 6264 .
Hannan NJ , Paiva P , Meehan KL , Rombauts LJ , Gardner DK , Salamonsen LA . Analysis of fertility-related soluble mediators in human uterine fluid identifies VEGF as a key regulator of embryo implantation . Endocrinology 2011 ; 152 : 4948 - 4956 .
Hannan NJ , Nie G , Rainzcuk A , Rombauts LJ , Salamonsen LA . Uterine lavage or aspirate: which view of the intrauterine environment? Reprod Sci 2012 ; 19 : 1125 - 1132 .
Hempstock J , Cindrova-Davies T , Jauniaux E , Burton GJ . Endometrial glands as a source of nutrients, growth factors and cytokines during the first trimester of human pregnancy: a morphological and immunohistochemical study . Reprod Biol Endocrinol 2004 ; 2 : 58 .
Hornung D , Lebovic DI , Shifren JL , Vigne JL , Taylor RN . Vectorial secretion of vascular endothelial growth factor by polarized human endometrial epithelial cells . Fertil Steril 1998 ; 69 : 909 - 915 .
Illera MJ , Lorenzo PL , Gui YT , Beyler SA , Apparao KB , Lessey BA . A role for alphavbeta3 integrin during implantation in the rabbit model . Biol Reprod 2003 ; 68 : 766 - 771 .
Ke LD , Shi YX , Yung WK. VEGF(121), VEGF(165) overexpression enhances tumorigenicity in U251 MG but not in NG-1 glioma cells . Cancer Res 2002 ; 62 : 1854 - 1861 .
Keyt BA , Berleau LT , Nguyen HV , Chen H , Heinsohn H , Vandlen R , Ferrara N. The carboxyl-terminal domain (111 - 165) of vascular endothelial growth factor is critical for its mitogenic potency . J Biol Chem 1996 ; 271 : 7788 - 7795 .
Lane M , Gardner DK . Increase in postimplantation development of cultured mouse embryos by amino acids and induction of fetal retardation and exencephaly by ammonium ions . J Reprod Fertil 1994 ; 102 : 305 - 312 .
Lane M , Gardner DK . Preparation of gametes, in vitro maturation, in vitro fertilization, embryo recovery and transfer . In: Gardner DK , Lane M , Watson AJ (eds). A Laboratory Guide to the Mammalian Embryo . New York: Oxford Press, 2004 , 24 - 40 .
Lane M , Gardner DK . Understanding cellular disruptions during early embryo development that perturb viability and fetal development . Reprod Fertil Dev 2005 ; 17 : 371 - 378 .
Lessey BA . Adhesion molecules and implantation . J Reprod Immunol 2002 ; 55 : 101 - 112 .
Licht P , Russu V , Wildt L . On the role of human chorionic gonadotropin (hCG) in the embryo-endometrial microenvironment: implications for differentiation and implantation . Semin Reprod Med 2001 ; 19 : 37 - 47 .
Ludwig AK , Sutcliffe AG , Diedrich K , Ludwig M . Post-neonatal health and development of children born after assisted reproduction: a systematic review of controlled studies . Eur J Obstet Gynecol Reprod Biol 2006 ; 127 : 3 - 25 .
Makinen S , Soderstrom-Anttila V , Vainio J , Suikkari AM , Tuuri T. Does long in vitro culture promote large for gestational age babies? Hum Reprod 2013 ; 28 : 828 - 834 .
Mascarenhas MN , Flaxman SR , Boerma T , Vanderpoel S , Stevens GA . National, regional, and global trends in infertility prevalence since 1990: a systematic analysis of 277 health surveys . PLoS Med 2012 ; 9 : e1001356 .
Mikolajczyk M , Wirstlein P , Skrzypczak J . Leukaemia inhibitory factor and interleukin 11 levels in uterine flushings of infertile patients with endometriosis . Hum Reprod 2006 ; 21 : 3054 - 3058 .
Moller B , Rasmussen C , Lindblom B , Olovsson M. Expression of the angiogenic growth factors VEGF, FGF-2, EGF and their receptors in normal human endometrium during the menstrual cycle . Mol Hum Reprod 2001 ; 7 : 65 - 72 .
Nakatsu MN , Sainson RC , Perez-del-Pulgar S , Aoto JN , Aitkenhead M , Taylor KL , Carpenter PM , Hughes CC . VEGF(121) and VEGF(165) regulate blood vessel diameter through vascular endothelial growth factor receptor 2 in an in vitro angiogenesis model . Lab Invest J Tech Methods Pathol 2003 ; 83 : 1873 - 1885 .
Navot D , Bergh P . Preparation of the human endometrium for implantation . Ann N Y Acad Sci 1991 ; 622 : 212 - 219 .
Noyes RW , Hertig AT , Rock J . Dating the endometrial biopsy . Am J Obstet Gynecol 1975 ; 122 : 262 - 263 .
Ogawa S , Oku A , Sawano A , Yamaguchi S , Yazaki Y , Shibuya M. A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain . J Biol Chem 1998 ; 273 : 31273 - 31282 .
Paiva P , Hannan NJ , Hincks C , Meehan KL , Pruysers E , Dimitriadis E , Salamonsen LA . Human chorionic gonadotrophin regulates FGF2 and other cytokines produced by human endometrial epithelial cells, providing a mechanism for enhancing endometrial receptivity . Hum Reprod 2011 ; 26 : 1153 - 1162 .
Papanikolaou EG , Camus M , Fatemi HM , Tournaye H , Verheyen G , Van Steirteghem A , Devroey P . Early pregnancy loss is significantly higher after day 3 single embryo transfer than after day 5 single blastocyst transfer in GnRH antagonist stimulated IVF cycles . Reprod Biomed Online 2006a ; 12 : 60 - 65 .
Papanikolaou EG , Camus M , Kolibianakis EM , Van Landuyt L , Van Steirteghem A , Devroey P. In vitro fertilization with single blastocyst-stage versus single cleavage-stage embryos . New Engl J Med 2006b; 354 : 1139 - 1146 .
Paria BC , Dey SK . Preimplantation embryo development in vitro: cooperative interactions among embryos and role of growth factors . Proc Natl Acad Sci USA 1990 ; 87 : 4756 - 4760 .
Pinborg A , Henningsen AK , Malchau SS , Loft A . Congenital anomalies after assisted reproductive technology . Fertil Steril 2013 ; 99 : 327 - 332 .
Poltorak Z , Cohen T , Sivan R , Kandelis Y , Spira G , Vlodavsky I , Keshet E , Neufeld G . VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix . J Biol Chem 1997 ; 272 : 7151 - 7158 .
Quinn P , Kerin JF , Warnes GM . Improved pregnancy rate in human in vitro fertilization with the use of a medium based on the composition of human tubal fluid . Fertil Steril 1985 ; 44 : 493 - 498 .
Rinaudo PF , Lamb J . Fetal origins of perinatal morbidity and/or adult disease . Semin Reprod Med 2008 ; 26 : 436 - 445 .
Scherrer U , Rimoldi SF , Rexhaj E , Stuber T , Duplain H , Garcin S , de Marchi SF , Nicod P , Germond M , Allemann Y et al. Systemic and pulmonary vascular dysfunction in children conceived by assisted reproductive technologies . Circulation 2012 ; 125 : 1890 - 1896 .
Soker S , Gollamudi-Payne S , Fidder H , Charmahelli H , Klagsbrun M. Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation by a peptide corresponding to the exon 7-encoded domain of VEGF165 . J Biol Chem 1997 ; 272 : 31582 - 31588 .
Soldi R , Mitola S , Strasly M , Defilippi P , Tarone G , Bussolino F . Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2 . EMBO J 1999 ; 18 : 882 - 892 .
Talaulikar VS , Arulkumaran S . Maternal, perinatal and long-term outcomes after assisted reproductive techniques (ART): implications for clinical practice . Eur J Obstet Gynecol Reprod Biol 2013 ; 170 : 13 - 19 .
Wahlsten D , Wainwright P . Application of a morphological time scale to hereditary differences in prenatal mouse development . J Embryol Exp Morphol 1977 ; 42 : 79 - 92 .
Wang C , Umesaki N , Nakamura H , Tanaka T , Nakatani K , Sakaguchi I , Ogita S , Kaneda K. Expression of vascular endothelial growth factor by granulated metrial gland cells in pregnant murine uteri . Cell Tissue Res 2000 ; 300 : 285 - 293 .
Ziebe S , Loft A , Povlsen BB , Erb K , Agerholm I , Aasted M , Gabrielsen A , Hnida C , Zobel DP , Munding B et al. A randomized clinical trial to evaluate the effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) in embryo culture medium for in vitro fertilization . Fertil Steril 2013 ; 99 : 1600 - 1609 .